Articles producció científica> Medicina i Cirurgia

In silico clinical trials for anti-aging therapies

  • Datos identificativos

    Identificador: imarina:5825619
    Autores:
    Menendez JCuyàs EFolguera-Blasco NVerdura SMartin-Castillo BJoven JAlarcón T
    Resumen:
    Therapeutic strategies targeting the hallmarks of aging can be broadly grouped into four categories, namely systemic (blood) factors, metabolic manipulation (diet regimens and dietary restriction mimetics), suppression of cellular senescence (senolytics), and cellular reprogramming, which likely have common characteristics and mechanisms of action. In evaluating the potential synergism of combining such strategies, however, we should consider the possibility of constraining trade-off phenotypes such as impairment in wound healing and immune response, tissue dysfunction and tumorigenesis. Moreover, we are rapidly learning that the benefit/risk ratio of aging-targeted interventions largely depends on intra- and inter-individual variations of susceptibility to the healthspan-, resilience-, and/or lifespan-promoting effects of the interventions. Here, we exemplify how computationally-generated proxies of the efficacy of a given lifespan/healthspan-promoting approach can predict the impact of baseline epigenetic heterogeneity on the positive outcomes of ketogenic diet and mTOR inhibition as single or combined anti-aging strategies. We therefore propose that stochastic biomathematical modeling and computational simulation platforms should be developed as in silico strategies to accelerate the performance of clinical trials targeting human aging, and to provide personalized approaches and robust biomarkers of healthy aging at the individual-to-population levels.
  • Otros:

    Autor según el artículo: Menendez J; Cuyàs E; Folguera-Blasco N; Verdura S; Martin-Castillo B; Joven J; Alarcón T
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Joven Maried, Jorge
    Palabras clave: Senolytics Inflammation Cancer Biomathematics Aging
    Resumen: Therapeutic strategies targeting the hallmarks of aging can be broadly grouped into four categories, namely systemic (blood) factors, metabolic manipulation (diet regimens and dietary restriction mimetics), suppression of cellular senescence (senolytics), and cellular reprogramming, which likely have common characteristics and mechanisms of action. In evaluating the potential synergism of combining such strategies, however, we should consider the possibility of constraining trade-off phenotypes such as impairment in wound healing and immune response, tissue dysfunction and tumorigenesis. Moreover, we are rapidly learning that the benefit/risk ratio of aging-targeted interventions largely depends on intra- and inter-individual variations of susceptibility to the healthspan-, resilience-, and/or lifespan-promoting effects of the interventions. Here, we exemplify how computationally-generated proxies of the efficacy of a given lifespan/healthspan-promoting approach can predict the impact of baseline epigenetic heterogeneity on the positive outcomes of ketogenic diet and mTOR inhibition as single or combined anti-aging strategies. We therefore propose that stochastic biomathematical modeling and computational simulation platforms should be developed as in silico strategies to accelerate the performance of clinical trials targeting human aging, and to provide personalized approaches and robust biomarkers of healthy aging at the individual-to-population levels.
    Áreas temáticas: Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Geriatrics & gerontology Ciências biológicas ii Ciências biológicas i Cell biology Biotecnología
    ISSN: 19454589
    Direcció de correo del autor: jorge.joven@urv.cat
    Identificador del autor: 0000-0003-2749-4541
    Fecha de alta del registro: 2024-09-07
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Aging-Us. 11 (16): 6591-6601
    Referencia de l'ítem segons les normes APA: Menendez J; Cuyàs E; Folguera-Blasco N; Verdura S; Martin-Castillo B; Joven J; Alarcón T (2019). In silico clinical trials for anti-aging therapies. Aging-Us, 11(16), 6591-6601. DOI: 10.18632/aging.102180
    DOI del artículo: 10.18632/aging.102180
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2019
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Cell Biology,Geriatrics & Gerontology
    Senolytics
    Inflammation
    Cancer
    Biomathematics
    Aging
    Odontología
    Nutrição
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Geriatrics & gerontology
    Ciências biológicas ii
    Ciências biológicas i
    Cell biology
    Biotecnología
  • Documentos:

  • Cerca a google

    Search to google scholar